Breast and ovarian cancer in the older woman

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2553-2561

  Tew, William P ^a   Muss, Hyman B ^b   Kimmick, Gretchen G ^c   Von Gruenigen, Vivian E ^d   Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADJUVANT CHEMOTHERAPY; ADVERSE OUTCOME; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DECISION MAKING; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY CANCER; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; AGE; AGED; BREAST NEOPLASMS; FEMALE; GERIATRIC ASSESSMENT; OVARIAN NEOPLASMS;

AGE FACTORS; AGED; BREAST NEOPLASMS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84906231055     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.3073     Document Type: Review

References (100)

1. Bastiaannet E, Liefers GJ, de Craen AJ, et al: Breast cancer in elderly compared to younger patients in the Netherlands: Stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 124:801-807, 2010
2. Anderson WF, Pfeiffer RM, Dores GM, et al: Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1899-1905, 2006 (Pubitemid 44664266)
3. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
4. Kimmick GG, Peterson BL, Kornblith AB, et al: Improving accrual of older persons to cancer treatment trials: A randomized trial comparing an educational intervention with standard information-CALGB 360001. J Clin Oncol 23:2201-2207, 2005 (Pubitemid 46218711)
5. Audisio RA, Bozzetti F, Gennari R, et al: The surgical management of elderly cancer patients: Recommendations of the SIOG surgical task force. Eur J Cancer 40:926-938, 2004 (Pubitemid 38496248)
6. Biganzoli L, Wildiers H, Oakman C, et al: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148-e160, 2012
7. Sandison AJ, Gold DM, Wright P, et al: Breast conservation or mastectomy: Treatment choice of women aged 70 years and older. Br J Surg 83:994-996, 1996 (Pubitemid 26228227)
8. Sweeney C, Schmitz KH, Lazovich D, et al: Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 98:521-529, 2006 (Pubitemid 43898815)
9. Hughes KS, Schnaper LA, Bellon JR, et al: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343. J Clin Oncol 31:2382-2387, 2013
10. Kunkler IH, Williams LW, Jack W, et al: The PRIME II trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation. Cancer Res 73, 2013 (suppl; abstr S2-01)
11. Blamey RW, Bates T, Chetty U, et al: Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer 49:2294-2302, 2013
12. Hind D, Wyld L, Beverley CB, et al: Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 1:CD004272, 2006
13. Van Limbergen E, Van der Schueren E, Van den Bogaert W, et al: Local control of operable breast cancer after radiotherapy alone. Eur J Cancer 26:674-679, 1990 (Pubitemid 20275098)
14. Arriagada R, Mouriesse H, Sarrazin D, et al: Radiotherapy alone in breast cancer: I. Analysis of tumor parameters, tumor dose and local control-The experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Int J Radiat Oncol Biol Phys 11:1751-1757, 1985 (Pubitemid 16224010)
15. Dowsett M, Cuzick J, Ingle J, et al: Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
16. Muss HB, Tu D, Ingle JN, et al: Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26:1956-1964, 2008
17. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
18. Amir E, Seruga B, Niraula S, et al: Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309, 2011
19. Mao JJ, Stricker C, Bruner D, et al: Patterns and risk factors associated with aromatase inhibitorrelated arthralgia among breast cancer survivors. Cancer 115:3631-3639, 2009
20. Silliman RA, Guadagnoli E, Rakowski W, et al: Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 20:2680-2688, 2002 (Pubitemid 34575641)
21. Buist DS, Chubak J, Prout M, et al: Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. J Clin Oncol 27:4508-4514, 2009
22. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293: 1073-1081, 2005 (Pubitemid 40300281)
23. Muss HB, Berry DA, Cirrincione C, et al: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B Experience. J Clin Oncol 25:3699-3704, 2007 (Pubitemid 47372610)
24. Daidone MG, Coradini D, Martelli G, et al: Primary breast cancer in elderly women: Biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 45:313-325, 2003 (Pubitemid 36299137)
25. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000 (Pubitemid 30212316)
26. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
27. Aapro M, Bernard-Marty C, Brain EG, et al: Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol 22:257-267, 2011
28. Königsberg R, Pfeiler G, Klement T, et al: Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (< 65) and elderly (≥ 65) patients. Eur J Cancer 48:2962-2968, 2012
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al: Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
30. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
31. Tolaney SM, Barry WT, Dang CT, et al: (suppl; abstr S1-04).
32. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
33. Shenoy C, Klem I, Crowley AL, et al: Cardiovascular complications of breast cancer therapy in older adults. Oncologist 16:1138-1143, 2011
34. Chavez-Macgregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222-4228, 2013
35. Kalam K, Marwick TH: Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and metaanalysis. Eur J Cancer 49:2900-2909, 2013
36. Hutchins LF, Unger JM, Crowley JJ, et al: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067, 1999 (Pubitemid 30035956)
37. Schneider M, Zuckerman IH, Onukwugha E, et al: Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: A population-based analysis. J Am Geriatr Soc 59:637-646, 2011
38. Carrick S, Parker S, Thornton CE, et al: Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2:CD003372, 2009
39. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
40. Hainsworth JD, Burris HA 3rd, Yardley DA, et al: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500-3505, 2001 (Pubitemid 32730087)
41. D'Hondt R, Paridaens R, Wildiers H, et al: Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: A phase II study. Anticancer Drugs 15:341-346, 2004 (Pubitemid 38526757)
42. ten Tije AJ, Smorenburg CH, Seynaeve C, et al: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer: A multicentre phase II trial. Eur J Cancer 40:352-357, 2004 (Pubitemid 38121271)
43. Del Mastro L, Perrone F, Repetto L, et al: Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: A phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 16:253-258, 2005 (Pubitemid 40309305)
44. Biganzoli L, Coleman R, Minisini A, et al: A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rev Oncol Hematol 61:84-89, 2007 (Pubitemid 44880151)
45. Bajetta E, Procopio G, Celio L, et al: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23:2155-2161, 2005 (Pubitemid 46218707)
46. Addeo R, Sgambato A, Cennamo G, et al: Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10:301-306, 2010
47. Lichtman SM, Hurria A, Cirrincione CT, et al: Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: Combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-638, 2012
48. Beuselinck B, Wildiers H, Wynendaele W, et al: Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology. Crit Rev Oncol Hematol 75:70-77, 2010
49. Hurria A, Fleming MT, Baker SD, et al: Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12:6100-6105, 2006 (Pubitemid 44703775)
50. Yancik R, Ries LA: Cancer in older persons: An international issue in an aging world. Semin Oncol 31:128-136, 2004 (Pubitemid 38481234)
51. Freyer G, Tew WP, Moore KN: Treatment and trials: Ovarian cancer in older women. Am Soc Clin Oncol Educ Book 2013:227-235, 2013
52. Hershman D, Jacobson JS, McBride R, et al: Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94:540-549, 2004 (Pubitemid 39024565)
53. Maas HA, Kruitwagen RF, Lemmens VE, et al: The influence of age and co-morbidity on treatment and prognosis in ovarian cancer: A populationbased study. Gynecol Oncol 97:104-109, 2005 (Pubitemid 40403681)
54. Tew WP, Java J, Chi D, et al: Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182). J Clin Oncol 28:397s, 2010 (suppl; abstr 5030)
55. Fairfield KM, Murray K, Lucas FL, et al: Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol 29:3921-3926, 2011
56. Tew W, et al: Management of ovarian and endometrial cancer in older adults, in Hurria A, Cohen HJ (eds): Practical Geriatric Oncology. Cambridge University, 2010
57. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002 (Pubitemid 34177431)
58. Hightower RD, Nguyen HN, Averette HE, et al: National survey of ovarian carcinoma: IV. Patterns of care and related survival for older patients. Cancer 73:377-383, 1994 (Pubitemid 24030617)
59. Pignata S, Vermorken JB: Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49:77-86, 2004 (Pubitemid 38084823)
60. Nordin AJ, Chinn DJ, Moloney I, et al: Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 81:447-455, 2001 (Pubitemid 32494661)
61. Cloven NG, Manetta A, Berman ML, et al: Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol 73:137-139, 1999 (Pubitemid 29177613)
62. Wright JD, Herzog TJ, Powell MA: Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190:1398-1400, 2004 (Pubitemid 38692227)
63. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003 (Pubitemid 46606249)
64. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338, 2009
65. Trédan O, Geay JF, Touzet S, et al: Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 18:256-262, 2007 (Pubitemid 46323090)
66. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006 (Pubitemid 43048949)
67. Vergote I, Tropé CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
68. Bookman M, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009
69. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
70. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
71. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996 (Pubitemid 26012496)
72. Fader AN, von Gruenigen V, Gibbons H, et al: Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 109:33-38, 2008
73. Pignata S, Breda E, Scambia G, et al: A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer: A Multicentre Italian Trial in Ovarian Cancer (MITO-5) study. Crit Rev Oncol Hematol 66:229-236, 2008
74. Pignata S, Monfardini S: Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 36:817-820, 2000 (Pubitemid 30214129)
75. Ceccaroni M, D'Agostino G, Ferrandina G, et al: Gynecological malignancies in elderly patients: Is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol 85:445-450, 2002 (Pubitemid 34651883)
76. Eisenhauer EL, Tew WP, Levine DA, et al: Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinumtaxane chemotherapy. Gynecol Oncol 106:381-387, 2007 (Pubitemid 47087938)
77. Hilpert F, du Bois A, Greimel ER, et al: Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged < or = 70 years with advanced ovarian cancer: A study by the AGO OVAR Germany. Ann Oncol 18:282-287, 2007 (Pubitemid 46323094)
78. Villella JA, Chaudhry T, Pearl ML, et al: Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 86:316-322, 2002 (Pubitemid 35425528)
79. Freyer G, Geay JF, Touzet S, et al: Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 16:1795-1800, 2005 (Pubitemid 41631242)
80. Kothari R, Nagel C, Koopmeiners JS, et al: The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Gynecol Oncol 119: 491-495, 2010
81. O'Cearbhaill R, Li D, Shi W, et al: Intraperitoneal chemotherapy in older women with epithelial ovarian cancer. J Geriatr Oncol 3:189-195, 2012
82. Glasgow MA, Yu H, Rutherford TJ, et al: Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). J Surg Oncol 107:195-200, 2013
83. McLean KA, Shah CA, Thompson SA, et al: Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol 118:43-46, 2010
84. Chi DS, Musa F, Dao F, et al: An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORT-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124: 10-14, 2012
85. Aletti GD, Dowdy SC, Podratz KC, et al: Analysis of factors impacting operability in stage IV ovarian cancer: Rationale use of a triage system. Gynecol Oncol 105:84-89, 2007 (Pubitemid 46441445)
86. Ledermann JA, Kristeleit RS, et al: Optimal treatment for relapsing ovarian cancer. Ann Oncol 21:vii218-vii222, 2010
87. Extermann M, Boler I, Reich RR, et al: Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377-3386, 2012
88. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
89. Teo MY, Power DG, Tew WP, et al: Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist 17:1450-1460, 2012
90. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003
91. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006 (Pubitemid 46630933)
92. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323-3329, 2010
93. Kurtz JE, Kaminsky MC, Floquet A, et al: Ovarian cancer in elderly patients: Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: A Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 22:2417-2423, 2011
94. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinumsensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
95. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al: Ovarian cancer, version 2.2013. J Natl Compr Canc Netw 11:1199-1209, 2013
96. Lichtman SM, Wildiers H, Chatelut E, et al: International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients-An analysis of the medical literature. J Clin Oncol 25:1832-1843, 2007 (Pubitemid 46860272)
97. Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34, 2007 (Pubitemid 46070218)
98. Mohile SG, Hardt M, Tew W, et al: Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist 18:408-414, 2013
99. Markman M, Webster K, Zanotti K, et al: Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 93:390-393, 2004 (Pubitemid 38507607)
100. Griffiths RW, Zee YK, Evans S, et al: Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer 21:58-65, 2011